11:43 AM EDT, 09/08/2025 (MT Newswires) -- BioNTech (BNTX) and Bristol Myers Squibb ( BMY ) said Monday that interim phase 2 data for pumitamig plus chemotherapy showed tumor shrinkage of 56.7% in patients with extensive-stage small cell lung cancer.

Of 43 patients enrolled in the trial, 38 were efficacy-evaluable who received pumitamig in combination with chemotherapy in two dose levels, the companies said.

The overall response rate was 76.3% and disease control rate was 100%, the companies said.

The study also showed a median progression free survival of 6.8 months and a "manageable" safety profile, the companies said.

Shares of BioNTech and Bristol Myers Squibb ( BMY ) were down 7.3% and 1.7%, respectively, in recent trading Monday.

Price: 104.30, Change: -8.16, Percent Change: -7.26